CORONAVIRUS INFO PROVIDED BY DR. JIM HARRIS – 03/29/2021
J. Harris: Scroll down to :
Then click the blue writing as above
Another way to click the same list in a different format.
“… the authors were able to determine that 3·27% of those who were uninfected during the first surge had a positive test during the second surge, compared with 0·65% among those who had previously recorded a positive test. Thus, they determined from that, in general, past infection confers 80·5% protection against reinfection, which decreases to 47·1% in those aged 65 years and older…the findings are similar in a sensitivity analysis of nurses, doctors, social workers, and health-care assistants who were tested regularly due to their profession.
“…many will find the data reported by Hansen and colleagues about protection through natural infection relatively alarming. Only 80·5% protection from reinfection in general, decreasing to 47·1% in people aged 65 years and older are more concerning figures than offered by previous studies. Until now, one of the largest datasets has come from Qatar during a period of high disease burden and reported an estimated reinfection risk of 0·2%.10…
“…emerging variants of concern might shift immunity below a protective margin, prompting the need for updated vaccines. Interestingly, vaccine responses even after single-dose are substantially enhanced in individuals with a history of infection with SARS-CoV-2.14 These data are all confirmation, if it were needed, that for SARS-CoV-2 the hope of protective immunity through natural infections might not be within our reach, and a global vaccination programme with high efficacy vaccines is the enduring solution.
(J. Harris: Data from Denmark which has uniform medical care which provides good computer data and widely available medical care.)
Emerging SARS-CoV-2 variants have raised concerns about resistance to neutralizing antibodies elicited by previous infection or vaccination. We examined whether sera from recovered and naïve donors collected prior to, and following immunizations with existing mRNA vaccines, could neutralize the Wuhan-Hu-1 and B.1.351 variants. Pre-vaccination sera from recovered donors neutralized Wuhan-Hu-1 and sporadically neutralized B.1.351, but a single immunization boosted neutralizing titers against all variants and SARS-CoV-1 by up to 1000-fold. Neutralization was due to antibodies targeting the receptor binding domain and was not boosted by a second immunization. Immunization of naïve donors also elicited cross-neutralizing responses, but at lower titers. Our study highlights the importance of vaccinating both uninfected and previously infected persons to elicit cross-variant neutralizing antibodies.
NEW YORK TIMES DATA FROM 3/28/21:
LAST BUT NOT LEASED:
GIVE US YOUR FEEDBACK. CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.